Haematological malignancies and acute leukaemia
Clinical research at Institut Paoli Calmettes is strongly centred on acute myeloid leukaemia, relapsed/refractory acute leukaemia, and other high-risk myeloid malignancies, with additional activity in broader haematological malignancies.
- Acute myeloid leukaemia
- Relapsed/refractory acute leukaemia
- Myelodysplastic syndromes
- High-risk myeloid malignancies
Research interest includes treatment-resistant disease, post-remission management, and transplant-related care in patients with aggressive blood cancers.
Allogeneic stem cell transplantation and conditioning regimens
The sponsor funds studies focused on allogeneic haematopoietic stem cell transplantation, including conditioning strategies and donor-related transplantation settings for patients with poor-prognosis myeloid disease.
- Busulfan-based conditioning
- Fludarabine combinations
- Thymoglobuline use
- Haploidentical transplantation
Attention is also given to transplant tolerance and immune complications in older patients and in those receiving matched related or unrelated donor grafts.
Graft-versus-host disease and immune prophylaxis
Another active area is the prevention of graft-versus-host disease after transplantation, with trials examining immune suppression approaches around engraftment and post-allograft care.
- Post-transplant ATG prophylaxis
- Neutrophil recovery-linked interventions
- Allograft immune management
- Transplant toxicity reduction
This area reflects a sustained focus on balancing anti-leukaemic control with immune-mediated complications after transplantation.
Breast cancer and HER2-related disease
Institut Paoli Calmettes also conducts research in advanced breast cancer, including HER2-negative inflammatory breast cancer, HER2-positive breast cancer, and HER2-low breast cancer.
- Inflammatory breast cancer
- Advanced breast cancer
- Hormone receptor-positive disease
- HER2-expressing tumours
Research activity includes immunotherapy, endocrine-resistant disease, and molecularly defined subgroups of metastatic breast cancer.
Targeted therapy and solid tumours
The sponsor’s portfolio extends to advanced solid tumours, with interest in targeted agents and treatment combinations across multiple tumour types, including breast, stomach, oesophagus, pancreas, endometrium, ovary, and lung cancers.
- ATR inhibition
- Endocrine-resistant breast cancer
- Immunotherapy combinations
- Multi-tumour solid cancer research
Work in this domain includes molecularly selected cancers and treatment-resistant advanced disease.
